Send us a text

Join us for Part 2 of our Metastatic Endometrial Cancer special with the amazing Dr Gemma Eminowicz from University College London Hospital.

In episode 1 we looked at molecular profiling and immunotherapy.

In this episode we explore the role of;

- hormone therapy

- Antibody drug conjugates

- PARP inhibitors

Endometrial cancer is taking off in terms of new and exciting treatment options.

Gemma does an amazing job talking us through them.

Enjoy.

Send us a text

Dr Gemma Eminowicz returns for 2026!!

Join us as we discuss the metastatic endometrial cancer landscape with Simply Oncology 'friend of the show' Dr Gemma Eminowicz from University College Hospital London.

Advanced endometrial cancer is so much more than carboplatin and paclitaxel. It now has the complete range of oncological treatments;

- Chemotherapy

- Immunotherapy

- Antibody Drug Conjugates

- Hormone therapy

- Targeted therapy

- Radiotherapy

We look at how the molecular testing in endometrial cancer has shaped advanced endometrial cancer therapy.

We look at the arrival of chemo-immunotherapy in the MMRd group and now in the MMRp patient group.

In the MMR proficient group we discuss the merits of 1st line Chemo-immunotherapy versus sequencing treatment to allow potential VEGF targeted therapy.

Gemma shares her invaluable experience and helps Mike understand advanced endometrial cancer.

Enjoy!!

Send us a text

We return for part 2 of our overview on metastatic oesphago-gastric cancer.

Join us as we welcome back Dr Lizzy Smyth from Oxford University Hospitals.

We look at the importance of nutritional support.

We discuss future directions such as CAR-T therapy

Lizzy mocks John (again!!)

A brilliant finish to our OG masterclass from Lizzy.

Enjoy!

Send us a text

Dr Lizzie Smith from Oxford University Hospitals gives us a an amazing 2 part overview of management of metastatic Oesophago-Gastric Cancer.

John gets put in his place

Send us a text

Happy New Year!!!

WE return in 2026 to complete our overview of PARPi in prostate cancer with the peerless Professor Rob Jones.

Send us a text

Join us as we unwind in the Christmas Holiday period with a masterful overview of PARP inhibitors in metastatic prostate cancer with Professor Rob Jones.

Rob is an old friend of the show and is amazing at setting the scene for who & when PARP inhibitors can be useful in metastatic prostate cancer.

Send us a text

Welcome back!

In part 1 we discussed the major effects of menopause and how these can be worsened by hormonal medications given to treat breast cancer and the impact these can have on patients completing treatment as planned.

In this episode we welcome back Dr Rebecca Bowen and discuss practical advice on managing these symptoms including a link to what will be a vital resource for all clinicians in Oncology and Primary Care: the Meno.Pause app.

Link below, download today!

Meno.Pause App

We wish all our wonderful listeners and guests a very Merry Christmas, thank you as always for tuning in,

John and Mike.

Send us a text

When is it safe to giving HRT in women who are being treated or have previously been diagnosed with breast cancer?

Will the use of vaginal oestrogens affect breast cancer outcomes?

What is the trade off on quality of life when symptoms of the menopause aren't managed?

Did you know that roughly 1 in 4 women stop their hormone therapy for breast cancer due to menopausal side effects!!

Who better to answer these questions and more than Dr Rebecca Bowen, Consultant Oncologist in Royal University Hospitals Bath who specialises in the treatment of breast and gynaecological cancers and heads up the specialist cancer and menopause unit.